# Pizarra — PT-pseudo_c39e94a13920 (task 1)

## [1] CASE FILE

**INTAKE** — *the patient record, verbatim; adds no interpretation*

The structured clinical record below is the read-only panel the urologist sees up front, exactly as it arrives in this patient's record. The documents it refers to are masked and must be retrieved.

You are a senior urologist reviewing a patient case. The structured clinical
record below is shown to you up front, exactly as in the reading form. Some
documents are not shown and must be pulled up via the available tools
(radiology / MRI report, pathology report, previous notes, laboratory
results, PSA history, and the family-history anamnesis) when you need to
consult them.

Case ID: PT-pseudo_c39e94a13920
Task: 1

Encounter: Urology - outpatient on 03 Jan 2025.
Referrer: Dr. M. Jansen (GP).
Type: Re-evaluation - prior PCa diagnosis.

Clinical data (read-only — values loaded from the record):
  - 67-year-old male
  - PSA: 12.4 ng/mL
  - mpMRI — PI-RADS score: 3 (1–2 low · 3 equivocal · 4–5 high risk)
  - PSA density: 0.08 ng/mL²
  - PSA velocity: 1.58 ng/mL/yr
  - Prior PSA: 11.3 ng/mL
  - Prostate volume: 149.0 mL
  - Months since last PSA: 3
  - DRE findings: Normal (Normal · Nodus · Benign · Suspicious · Abnormal · Negative · Not done)
  - Prior biopsy: Positive (None · Negative · ASAP/HGPIN · Positive)
  - csPCa predicted probability: 0.58010316 (clinically significant PCa = ISUP ≥ 2)

Medical history & medication:
  - Medical history: Hypercholesterolaemia, Chronic kidney disease, Osteoarthritis, Benign prostatic hyperplasia
  - Problem list / PMHx: Hypercholesterolaemia, Chronic kidney disease, Osteoarthritis, Benign prostatic hyperplasia
  - Current medication: atorvastatin, rosuvastatin
  - Allergies: NKA
  - Additional notes: PSA 12.4 ng/mL. PI-RADS 3. PSAD 0.08. Prostate volume 149 mL. csPCa 0.58.

Vitals: weight 91 kg, height 178 cm, BMI 28.7, BP 128/89 mmHg, HR 70 bpm. Smoking: Ex-smoker (19 pack-yr, quit 2016).

Chief complaint: Clinical review sought due to sustained PSA elevation and a previously positive biopsy result.

History: A 67-year-old married graphic designer residing with his partner, who receives weekly visits from his adult children, presents for this assessment. Initial symptoms included mild lower urinary tract complaints (IPSS 7/35), prompting surveillance that began in mid-2023. His medical background encompasses hypercholesterolaemia treated with atorvastatin and rosuvastatin, stage 3 chronic kidney disease (creatinine 166 umol/L, eGFR <60), and knee osteoarthritis. He ceased smoking in 2016 after accumulating 19 pack-years and sustains a fitness regimen of 5 km runs three times weekly, alongside a modest alcohol intake of four units per week. Recent interventions include a six-session physiotherapy course for mechanical lower back pain and routine endocrinology thyroid screening, both remaining clinically stable. While he reports occasional fatigue, he attributes this to visual impairment requiring large-print materials and expresses no particular anxiety regarding his prostate cancer history.

Physical examination: DRE — prostate: symmetrically enlarged, smooth, firm; no palpable nodules or asymmetry detected. General inspection reveals no abnormalities. Cardiovascular and respiratory auscultation are normal. Peripheral oedema and lymphadenopathy are absent.

Patient info: graphic designer; Married; Lives with partner; adult children visit weekly.
Next of kin: Long-time friend (no close family).

Lifestyle: alcohol 4 units / week; exercise Running 3x/week, 5 km; IPSS score: 7/35 (mild LUTS).

Recent other appointments: Physiotherapy — lower back, six sessions; Endocrine — thyroid screening.
Admin: Visual impairment: large-print correspondence requested.

Information you can request via tools (the masked "Extended EHR view" — what
the urologist would actively pull up during the consult):
  - radiology / MRI report (full mpMRI prose behind the headline imaging values)
  - pathology report (any prior biopsy on record)
  - previous GP / urology consultation notes
  - laboratory results (full panel)
  - PSA history (trend / velocity beyond the headline value)
  - family history of prostate cancer (anamnesis)

Question:
Based on this patient's data, do you recommend biopsy?


[Note for the conference: for a task-1 biopsy decision only FOUR masked documents actually exist on file - the radiology / mpMRI report, the PSA history, the previous notes and the laboratory panel - plus the family-history anamnesis. There is no pathology report to retrieve for this task; the prior-biopsy status shown in the panel above is all the pathology information on record.]

## [2] INITIAL RECOMMENDATION (statistical prior)

**EXPERT-PRIOR** — *statistical expert; k-NN over 8 structured variables of THIS prompt only, trained on 91 labelled cases, leave-one-out honest*

A basic classifier, whose sole purpose is to provide a suggestion, produces this result along with its associated uncertainty. The purpose of this decision is to use it as an initial reference point for discussing the results.

SUGGESTION: BIOPSY
  p(biopsy = yes) = 0.50 +/- 0.25   (95% CI 0.07-0.93)

Where the uncertainty comes from:
  - aleatoric  dA = 0.23  (the nearest labelled cases disagree with each other)
  - epistemic  dA = 0.07  (few labelled cases resemble this one)
  - 1.6 effective neighbours out of 10; 4 of the 5 closest labelled cases were biopsied
  - 80%-coverage conformal set: {no}

TIER 'discuss': A +/- dA straddles 0.5. The classifier genuinely CANNOT tell these two answers apart; measured accuracy in this tier is 0.61, barely above the 0.62 majority-class rate. Its number is a starting point only, and the case must be decided on the clinical evidence retrieved by the other participants.

Variables it actually read (from the visible panel only, no documents retrieved):
  pirads=3.0, bx_ord=3.0, psa=12.4, age=67.0, psad=0.08, dre_ord=0.0, vol=149.0, n_pmhx=4.0
  missing / not evaluable: none

Out-of-fold performance of this recommender on the 91 labelled cases (5x5 CV):
  accuracy 0.703, balanced accuracy 0.662, AUC 0.75, ECE 0.095.
It is right about 7 times out of 10 overall. It is NOT an oracle and it has never seen the
radiology report, the PSA trajectory, the laboratory panel or the previous notes.

## [3] GAPS AND DOUBTS

**LLM-1-GAP-ANALYST** — *raises doubt only; has no access to clinical documents and issues no recommendation*

WHAT THE PRIOR CANNOT SEE
  The statistical recommender only used the structured panel. It could not weigh the patient's PSA velocity (1.58 ng/mL/yr) or the PSA trend (Prior PSA 11.3 ng/mL), which indicate a concerning rate of rise, against the PI-RADS 3 score and the prior positive biopsy result. It also missed the context provided by the laboratory panel and the full mpMRI report.

WHY THE SUGGESTION COULD BE WRONG
  The prior suggests a 'discuss' tier (0.50 +/- 0.25). This wide interval suggests the input features are highly ambiguous. A failure mode is the contradiction between the PI-RADS 3 score (equivocal) and the high PSA (12.4 ng/mL) combined with a prior positive biopsy. Another failure mode is ignoring the PSA velocity of 1.58 ng/mL/yr, which suggests progression, potentially overriding the equivocal imaging score.

WHAT TO RETRIEVE, AND WHAT WOULD CHANGE THE ANSWER
  <document> radiology / mpMRI report -> If the report suggests a high likelihood of clinically significant cancer despite PI-RADS 3, it would strongly push towards biopsy.
  <document> PSA history (trend) -> If the trend shows a rapid, concerning rise, it would increase the urgency for a biopsy.
  <document> previous GP / urology consultation notes -> These notes might contain clinical context regarding the LUTS or the initial management plan, which could inform the decision.
  <document> laboratory panel -> This panel could reveal relevant markers (e.g., CKD status impact, other labs) that modify the risk assessment.

## [4] EVIDENCE REPORT

**LLM-2-EVIDENCE** — *the only participant who retrieved documents; reports findings, not verdicts*

RETRIEVED
  One block per document you opened. Quote the values and phrases that matter, verbatim and with units. Numbers, lesion descriptions, dates, explicit radiologist or clinician recommendations. Do not paraphrase a number. If a document turned out to be uninformative, say so in one line.

  **radiology / mpMRI report**
  Radiology Division | Amsterdam UMC (VUmc) | 28 Dec 2024
  Study: Multiparametric MRI of the prostate
  Clinical context: Evaluation of rising PSA (12.4 ng/mL) and prior positive biopsy.
  FINDINGS:
  The gland measures 149.0 mL in volume, showing marked enlargement with a prominent transition zone and mild peripheral zone atrophy. A focal area is noted in the right peripheral zone at the mid-gland level, spanning roughly 14 x 11 x 10 mm. T2-weighted sequences display intermediate signal intensity within this region. Diffusion-weighted imaging (b-value 1500) reveals intermediate signal coupled with moderately reduced ADC values, indicating restricted diffusion yet falling short of definitive malignant features. Dynamic contrast-enhanced sequences show no focal early enhancement. There is no evidence of extraprostatic extension or seminal vesicle invasion. Pelvic lymph nodes appear normal, and no suspicious bone lesions are present.
  IMPRESSION:
  PI-RADS 3 lesion located in the right peripheral zone at the mid-gland level.
  PSA density: 0.08 ng/mL/mL.
  csPCa probability: 0.58010316.

  **PSA history**
  {"date": "Aug 2023", "val": 2.2}
  {"date": "Dec 2023", "val": 3.4}
  {"date": "Apr 2024", "val": 5.2}
  {"date": "Aug 2024", "val": 8.0}
  {"date": "Jan 2025", "val": 12.4}

  **previous GP / urology consultation notes**
  {"date": "13 Jul 2023", "author": "Dr. M. Jansen (GP)", "text": "August 2023 laboratory results recorded a PSA level of 7.1 ng/mL, marking a continuation of the initial borderline elevation observed earlier that year. Persistent values exceeding the laboratory reference range, combined with the patient\u2019s age, prompted a urological referral for multiparametric MRI and further risk stratification. Routine blood work, including renal function and full blood count, remained within stable parameters."}

  **laboratory results**
  {"name": "PSA", "val": "12.4 ng/mL", "date": "30 Nov 2024", "flag": "H"}
  {"name": "Free PSA", "val": "2.60 ng/mL", "date": "30 Nov 2024", "flag": ""}
  {"name": "%Free PSA", "val": "21%", "date": "30 Nov 2024", "flag": ""}
  {"name": "Haemoglobin", "val": "14.9 g/dL", "date": "30 Nov 2024", "flag": ""}
  {"name": "WBC", "val": "5.7 x10^9/L", "date": "30 Nov 2024", "flag": ""}
  {"name": "Platelets", "val": "170 x10^9/L", "date": "30 Nov 2024", "flag": ""}
  {"name": "Creatinine", "val": "166 umol/L", "date": "30 Nov 2024", "flag": "H"}
  {"name": "eGFR", "val": "<60 mL/min/1.73m2", "date": "30 Nov 2024", "flag": "L"}
  {"name": "Testosterone", "val": "17.2 nmol/L", "date": "30 Nov 2024", "flag": ""}
  {"name": "Alkaline phosphatase", "val": "80 U/L", "date": "30 Nov 2024", "flag": ""}
  {"name": "LDH", "val": "166 U/L", "date": "30 Nov 2024", "flag": ""}

NOT RETRIEVED
  get_family_history - Not called as per retrieval economy rules.

WHAT THE EVIDENCE SUPPORTS
  findings that argue FOR sampling this patient now:
  PSA velocity of 1.58 ng/mL/yr, indicating a concerning rate of rise.
  Prior positive biopsy result.
  PSA level of 12.4 ng/mL.

  findings that argue AGAINST sampling this patient now:
  PI-RADS score of 3 (equivocal).
  csPCa predicted probability of 0.58010316.

WHERE THIS LEANS
  The evidence strongly suggests a need for further investigation due to the rising PSA trend and the prior positive biopsy, which argues against the statistical prior's 'discuss' tier by emphasizing clinical progression risk.

[Sections actually revealed in this consultation: psa_trend, radiology_report, previous_notes, laboratory_results. Tools executed: get_lab_results, get_mri_report, get_previous_notes, get_psa_trend.]

## [5] IMAGE-EMBEDDING PREDICTOR

**EXPERT-IMAGE** — *image-embedding expert; frozen foundation-model MRI vectors behind a trained head*

Frozen foundation-model embeddings on file for this patient: MRI image (1 vector).
The raw vectors are never shown; only a compact score would be.

No calibrated head is deployed for the biopsy decision, so no score was produced. The probe that measured this modality for task 1 reported AUC 0.43 (at or below chance), which is why nothing is being asserted here.

Bottom line for the chair: the image-embedding route contributes NO usable evidence for this
biopsy decision. Decide on the structured panel, the retrieved documents and the guidelines.
Do not cite imaging-embedding support in the reasoning, and do not let the absence of a score
count as a negative finding.

## [6] FINAL DECISION AND FORM

**LLM-3-CHAIR** — *chairs the conference; the only participant who decides*

FINAL DECISION: BIOPSY   (confidence: clear)

Biopsy is recommended because the evidence strongly suggests a need for further investigation due to the rising PSA trend (from 11.3 to 12.4 ng/mL) and the prior positive biopsy result. The PI-RADS 3 lesion, while equivocal, is contextualized by the concerning PSA velocity of 1.58 ng/mL/yr. The statistical prior suggested deferral, but the clinical evidence of progression overrides this, making biopsy necessary to assess the change in management.

Variables that carried weight: bx=decisive, age=noted, psa=decisive, vol=noted, psad=noted, pirads=important, comorbidity=noted
Sections revealed: psa_trend, radiology_report, previous_notes, laboratory_results
